XML 17 R2.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current Assets:    
Cash and cash equivalents $ 154,901 $ 128,994
Marketable securities 236,949 213,591
Accounts receivable, net of reserves of $4,523 in 2016 and $5,128 in 2015 204,494 188,318
Inventories 158,034 188,833
Deferred income tax assets   39,829
Other current assets 91,206 62,069
Total current assets 845,584 821,634
Long-Term Assets:    
Property and equipment, net 357,422 333,026
Goodwill 178,228 178,934
Intangible assets, net 46,155 55,909
Other long-term assets 103,315 85,490
Total long-term assets 685,120 653,359
TOTAL ASSETS 1,530,704 1,474,993
Current Liabilities:    
Accounts payable 60,057 52,648
Accrued liabilities 236,131 205,530
Line of credit 611,000 573,000
Current portion of deferred revenue 27,380 25,583
Total current liabilities 934,568 856,761
Long-Term Liabilities:    
Deferred income tax liabilities 39,287 49,389
Long-term debt 593,110 597,085
Long-term deferred revenue, net of current portion 33,015 27,055
Other long-term liabilities 38,937 28,698
Total long-term liabilities 704,349 702,227
Total liabilities 1,638,917 1,558,988
Commitments and Contingencies (Note 14)
Stockholders’ Equity (Deficit):    
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 103,341 shares in 2016 and 102,237 shares in 2015 10,334 10,258
Additional paid-in capital 1,011,895 940,534
Deferred stock units: Outstanding: 231 units in 2016 and 240 units in 2015 5,514 5,409
Retained earnings 540,401 318,356
Accumulated other comprehensive loss (43,053) (42,265)
Treasury stock, at cost: 15,367 shares in 2016 and 12,242 shares in 2015 (1,633,443) (1,316,417)
Total IDEXX Laboratories, Inc. stockholders’ equity (deficit) (108,352) (84,125)
Noncontrolling interest 139 130
Total stockholders’ equity (deficit) (108,213) (83,995)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) $ 1,530,704 $ 1,474,993